The present invention concerns
clusterin for use in the treatment of thrombotic microangiopathies, and a pharmaceuti- cal composition comprising
clusterin for use in the treatment of thrombotic microangiopathies, said composition not comprising
von Willebrand factor
protease. The present invention also concerns an
ex vivo method for stratifying a patient suffering, or likely to be suffering, from TMA, comprising the following steps: 1) measuring, in a biological sample from said patient, the amount L<com:Sub>C< / com:Sub> of
clusterin, and 2) comparing the amount <com:Math><
semantics>Lc<
annotation encoding="application / x-tex">L_c< /
annotation>< /
semantics>< / com:Math> measured in step 1) with an amount <com:Math><
semantics>Lref<
annotation encoding="application / x-tex">L_{ref}< / annotation>< / semantics>< / com:Math> of clusterin by calculating the
score S1= <com:Math><semantics>LC / Lref<annotation encoding="application / x-tex">L_C / L_{ref}< / annotation>< / semantics>< / com:Math>, in which: • If <com:Math><semantics>S1≤1<annotation encoding="application / x-tex">S1 \le 1< / annotation>< / semantics>< / com:Math>, the patient is considered to be likely to benefit from a treatment of the TMA with clusterin, • If <com:Math><semantics>S1>1<annotation encoding="application / x-tex">S1 > 1< / annotation>< / semantics>< / com:Math>